Korro Bio, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $19.6 million, a decrease from a net loss of $23.4 million in the same period last year. The company did not generate any revenue from product sales during this quarter, compared to $2.6 million in collaboration revenue recognized in the first quarter of 2025. The decline in revenue is attributed to a 12-month pause in its collaboration agreement with Novo Nordisk, which began in November 2025. As of March 31, 2026, Korro's accumulated deficit stood at $403.5 million.
Total operating expenses for the first quarter of 2026 were $20.4 million, down from $27.6 million in the prior year. This reduction was primarily driven by a significant decrease in research and development expenses, which fell to $12.9 million from $19.7 million. The decrease in R&D spending was largely due to the termination of the Phase 1/2a REWRITE clinical trial for KRRO-110, as well as a reduction in personnel-related expenses following workforce reductions implemented in 2025. General and administrative expenses also saw a slight decline, totaling $7.5 million compared to $7.8 million in the previous year.
Korro Bio's financial position improved significantly, with cash, cash equivalents, and marketable securities totaling $157.1 million as of March 31, 2026, up from $25.2 million at the end of 2025. This increase was bolstered by a private placement completed in March 2026, which raised approximately $85 million, and additional funds from an at-the-market equity program. The company anticipates that its current cash reserves will be sufficient to fund operations into the second half of 2028.
In terms of operational developments, Korro Bio is advancing its KRRO-121 program, a potential treatment for hyperammonemia, with plans to file for regulatory approval to commence human trials in the second half of 2026. The company is also on track to announce a development candidate for its next-generation GalNAc-conjugated program targeting alpha-1 antitrypsin deficiency (AATD) in the second quarter of 2026. Despite the challenges faced, including the pause in collaboration with Novo Nordisk and ongoing operational losses, Korro Bio remains focused on its strategic objectives and the advancement of its pipeline candidates.
About Korro Bio, Inc.
Korro Bio is a clinical-stage biopharmaceutical company developing RNA editing therapies to treat rare and prevalent diseases. Using its proprietary OPERA platform, it designs oligonucleotides to recruit endogenous ADAR enzymes for precise, transient RNA modifications. Its focus includes gene repair, protein modulation, and addressing undruggable targets, with a pipeline targeting conditions like alpha-1 antitrypsin deficiency, leveraging established delivery methods and aiming for disease-modifying, safe, and scalable genetic medicines.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.